Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Christine Langer; Claus Wittekindt; Gregor Wolf

doi:10.1055/a-1132-0051

Onkologie up2date, Table of Contents

Onkologie up2date 2020; 2(02): 107-118
DOI: 10.1055/a-1132-0051

Tumoren der Atemwege

Georg Thieme Verlag KG Stuttgart · New York

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Christine Langer

,

Claus Wittekindt

,

Gregor Wolf

Abstract

All articles of this category

Die rezidivierende respiratorische Papillomatose (RRP) – ausgelöst durch das humane Papillomavirus (HPV) – ist durch warzenartige Veränderungen der Atemwege gekennzeichnet. Der klinische Verlauf ist variabel, die Diagnosestellung erfolgt nicht selten wesentlich später als der Symptombeginn, insbesondere bei Kindern. Die Behandlung wird individuell festgelegt und umfasst meist Operationen zur Tumorkontrolle und zum Erhalt der Stimmfunktion.

Full Text

References

Literatur
1 Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118: 450-454
2 Gallagher TQ, Derkay CS. Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion. Expert Opin Pharmacother 2009; 10: 645-655
3 Lindeberg H, Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965–1984. Clin Otolaryngol Allied Sci 1990; 15: 125-131
4 Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008; 118: 1236-1247
5 Buchinsky FJ, Donfack J. Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS One 2008; 28: e2263
6 Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125: 743-748
7 Munoz N, Bosch FX, de Sanjosé S. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-552
8 Rabah R, Lancaster WD, Thomas R. et al. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001; 4: 68-72
9 Kashima HK, Kessis T, Mounts P. et al. Polymerase chain reaction identification of human papillomavirus DNA in CO₂ laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991; 104: 191-195
10 Kashima H, Wu TC, Mounts P. et al. Carcinoma ex-papilloma: histologic and virologic studies in whole-organ sections of the larynx. Laryngoscope 1988; 98 (6 Pt 1): 619-624
11 Yoshpe NS. Oral and laryngeal papilloma: a pediatric manifestation of sexually transmitted disease?. Int J Pediatr Otorhinolaryngol 1995; 31: 77-83
12 Fredericks BD, Balkin A, Daniel HW. et al. Transmission of human papillomaviruses from mother to child. Aust N Z J Obstet Gynaecol 1993; 33: 30-32
13 McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005; 69: 597-605
14 Shah KV, Stern WF, Shah FK. et al. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis 1998; 17: 372-376
15 Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010; 118: 450-454
16 Kashima H, Shah F, Lyles A. A comparison of risk factors in juvenile-onset and adult-onset respiratory papillomas. Laryngoscope 1992; 102: 9-13
17 Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001; 111: 57-69
18 Reeves WC, Ruparelia SS, Swanson KI. et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982
19 Silver RD, Rimell FL, Adams GL. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2003; 129: 622-629
20 Abramson AL, Nouri M, Mullooly V. et al. Latent Human Papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004; 72: 473-477
21 Leunig A, Betz CS, Mehlmann M. A pilot series demonstrating fluorescence staining of laryngeal papilloma using 5-aminolevulinic acid. Laryngoscope 2000; 110: 1783-1785
22 Derkay CS, Hester RP, Burke P. et al. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2004; 68: 1493-1498
23 Reeves WC, Ruparelia SS, Swanson KI. et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982
24 Tasca RA, McCormick M, Clarke RW. British Association of Paediatric Otorhinolaryngology members experience with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2006; 70: 1183-1187
25 Pasquale K, Wiatrak B, Woolley A. et al. Microdebrider versus CO₂ laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003; 113: 139-143
26 Schraff S, Derkay CS, Burke B. et al. American Society of Pediatric Otolaryngology membersʼ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004; 130: 1039-1042
27 Andratschke A, Betz C, Leunig A. Larynxpapillomatose, Ätiologie, Diagnostik und Therapie. HNO 2008; 56: 1190-1196
28 Johnson K, Derkay C. Palliative aspects of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2009; 42: 57-70
29 Kashima HK, Kessis T, Mounts P. et al. Polymerase chain reaction identification of human papillomavirus DNA in CO₂ laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991; 104: 191-195
30 Hartnick CJ, Boseley ME, Franco RA. et al. Efficacy of treating children with anterior commissure and true vocal fold respiratory papilloma with the 585-nm pulsed-dye laser. Arch Otolaryngol Head Neck Surg 2007; 133: 127-130
31 Carifi M, Napolitano D, Morandi M. et al. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015; 11: 731-738
32 Healy GB, Gelber RD, Trowbridge AL. et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988; 319: 401-407
33 Maunsell R, Bellomo-Brandao AM. Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child. A case report. Sao Paolo Med J 2018; 136: 376-381
34 Holland B, Koufman J, Postma G. et al. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002; 112: 1926-1929
35 Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004; 18: 248-253
36 Abramson AL, Shikowitz MJ, Mullooly VM. et al. Variable light-dose effect on photodynamic therapy for laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1994; 120: 852-855
37 Shikowitz MJ, Abramson AL, Steinberg BM. et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004; 131: 99-105
38 Pudzuhn A, Welzel C, Bloching M. et al. Intralesional cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol 2007; 264: 63-70
39 Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003; 113: 1583-1587
40 Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English language literature. Otolaryngol Head Neck Surg 2007; 136: 863-869
41 Bedard J, May S, Lis M. et al. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrob Agents Chemother 1999; 43: 557-567
42 Nawka T. Larynxpapillomatose. Laryngorhinootologie 2018; 97: 670-671
43 Best SR, Mohr M, Zur KB. Systemic bevcizumab for recurrent respiratory papillomatosis: A national survey. Laryngoscope 2017; 127: 2225-2229
44 Sidell DR, Nassar M, Cotton RT. et al. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2014; 123: 214-221
45 Yiu Y, Fayson S, Smith H. et al. Implementation of Routine HPV Vaccination in the Management of Recurrent respiratory Papillomatosis. Ann Otol Rhinol Laryngol 2019; 128: 309-315
46 Papaioannou VA, Arens C. Behandlungsergebnisse der rezidivierenden respiratorischen Papillomatose mit Gardasil. Laryngorhinootologie 2018; 97 (02) 213
47 Papaioannou VA, Lux A, Zimmermann S. et al. Behandlungsergebnisse bei rezidivierender respiratorischer Papillomatose – retrospektive Analyse juvenile und adulter Fälle. HNO 2017; 65: 923-932
48 Hall MT, Simms KT, Lew JB. et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 2019; 4: e19-e27
49 Novakovic D, Cheng ATL, Zurynski Y. et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis 2018; 217: 208-212